Congress has until the end of September to reauthorize the Food and Drug Administration’s user fee programs. The package of legislation provides funding for reviewing devices, pharmaceuticals and other medical products over the next five years.
A version of the bill has passed the U.S. House of Representatives, but its equivalent has yet to pass the full U.S. Senate. As legislators prepare for their August recess, members of the House Energy and Commerce Committee have pressed the Senate to “act urgently” to meet its deadline.
